Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-07-23

Clinical Trial Update: Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia [Phase 3]

View source ↗

Summary

Phase 3 trial update on intravitreal bevacizumab for idiopathic macular telangiectasia, with the study status shown as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avastin (bevacizumab)

Snippet

Sponsor: University of Sao Paulo | Conditions: Retina, Telangiectasis | Phase 3 | Status: COMPLETED